CNBX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 21:56):

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer...

Stats
Tagesvolumen	139 615
Durchschnittsvolumen	231 573
Marktkapitalisierung	354 670
EPS	$0 ( 2024-04-14 )
Nächstes Ertragsdatum	( $0 ) 2024-07-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2014-07-25	Cannabics Inc.	Buy	18 239 594	COMMON STOCK
2014-06-23	Cannabics Inc.	Buy	14 525 000	Common Stock
2014-05-08	Cannabics Inc.	Buy	20 500 000	Common Stock
2014-05-08	Mills Thomas E	Sell	20 500 000	common stock
2014-04-25	Mills Thomas E	Buy	20 500 000	common stock

INSIDER POWER
0.00
Last 15 transactions
Buy: 135 764 594 \| Sell: 73 500 000

Cannabics Pharmaceuticals Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Cannabics Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$410 165
Bruttogewinn:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2023
Umsatz:	$410 165
Bruttogewinn:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2022
Umsatz:	$29 958.00
Bruttogewinn:	$-168 569 (-562.68 %)
EPS:	$-3.08

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.0200

Financial Reports:

No articles found.

Cannabics Pharmaceuticals

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.